Swanhill Capital LLC is a partnership dedicated to actively pursuing investments in healthcare companies, excluding life science. We are committed to long-term capital appreciation and to expanding our investment portfolio.
We opportunistically participate as a minority or control investor by infusing capital in companies at all phases of their life cycle from a seed round to a traditional buyout.
Our team has several years of experience in evaluating companies in a variety of industries throughout all economic and business cycles. We are methodical and meticulous in our assessment of opportunities, and employ a rigorous set of due diligence procedures in our analysis. We seek to uncover and extract intrinsic value that others do not perceive.
We strive to be creative in our structuring approach to consummate transactions expeditiously. We understand the need to be nimble and decisive in this competitive marketplace in order to capitalize on investment opportunities.
We are patient investors. We are not in the business of acquiring companies with the expectation of harvesting them in the short-term for profit. Rather, we partner with management and seek to nurture our investments for long-term growth and cash flow generation.
We understand the importance of instilling a culture of excellence in our portfolio companies through disciplined operating procedures designed to achieve superior results. We challenge management to realize the full potential of a company by driving top line growth and cash flow without sacrificing the commitment to contain costs and improve operating margins. We work side by side as a team in developing and executing strategy to achieve this end.
PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA.
RxREVU is the leader in prescription decision support. Its analytics platform is designed to assist healthcare providers and patients at the point of care.